Glutamate-Mediated Signaling and Autism Spectrum Disorders: Emerging Treatment Targets

E-ISSN： 1873-4286|20|32|5186-5193

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.20, Iss.32, 2014-10, pp. : 5186-5193

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Treatment of autism spectrum disorders: neurotransmitter signaling pathways involved in motivation and reward as therapeutic targets

By Walker Michael A

Expert Opinion on Therapeutic Targets, Vol. 12, Iss. 8, 2008-08 ,pp. : 949-967

Informa Healthcare

Access to resources Recommend Favorite

Emerging drugs for the treatment of symptoms associated with autism spectrum disorders

By Wink Logan K Plawecki Martin H Erickson Craig A Stigler Kimberly A McDougle Christopher J

Expert Opinion on Emerging Drugs, Vol. 15, Iss. 3, 2010-09 ,pp. : 481-494

Informa Healthcare

Access to resources Recommend Favorite

Autism spectrum disorders: emerging pharmacotherapy

By Bostic Jeff Q King Bryan H

Expert Opinion on Emerging Drugs, Vol. 10, Iss. 3, 2005-08 ,pp. : 521-536

Informa Healthcare

Access to resources Recommend Favorite

Editorial (Thematic Issue: New Therapeutic Targets for Autism Spectrum Disorders)

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 15, Iss. 5, 2016-05 ,pp. : 529-532

Bentham Science Publishers

Access to resources Recommend Favorite

The Role of Ionotropic Glutamate Receptors in Childhood Neurodevelopmental Disorders: Autism Spectrum Disorders and Fragile X Syndrome

Current Neuropharmacology, Vol. 12, Iss. 1, 2014-01 ,pp. : 71-98

Bentham Science Publishers

Access to resources Recommend Favorite